The compounds including SAR502250 [132], AR-A014418 [133, 134], MMBO [135], (R)-rescovitine [136], MW181 [137], SB239063 [137], bosutinib [138], SM07883 [139], Dyrk1-inh [140], DYR219 [141], BAY61-3606 [142] and Fasudil [143] are yet to be tested at clinical front for AD, whereas, lithium, tideglusib, nilotinib, and dl-3-n-butylphthalide have already made a headway to clinical trials. Here, DYRK1A is linked to Alzheimer disease.